Five Stocks To Buy: SBI Life Insurance, Prestige Estates, Biocon Among Others
Here’s a detailed look at each stock along with their target levels and stop-loss recommendations.
Aditya Agarwala, Head of Research and Investments at Invest4edu, and Nilesh Jain, Head VP of Technical & Derivatives Research at Centrum Broking Ltd, have identified five stocks for investors to consider on Tuesday. The stocks recommended include SBI Life Insurance Ltd., Prestige Estates Projects Ltd., Piramal Pharma Ltd., Macrotech Developers Ltd. (Lodha), and Biocon Ltd. Here’s a detailed look at each stock along with their target levels and stop-loss recommendations.
Aditya Agarwala from Invest4edu has recommended a buy on SBI Life Insurance with a target price of Rs 1,950 and a stop-loss at Rs 1,800. Out of 37 analysts tracking the company, 35 maintain a 'buy' rating and two recommend a 'hold,' according to Bloomberg data. The average 12-month consensus price target implies an upside of 10.7%
Another recommendation from Aditya Agarwala is Prestige Estates Projects, with a target of Rs 1,940 and a stop-loss at Rs 1,630. Out of 20 analysts tracking the company, 18 maintain a 'buy' rating, one recommend a 'hold,' and one suggest 'sell,' according to Bloomberg data. The average 12-month consensus price target implies an upside of 8%
Piramal Pharma is also on Agarwala's buy list, with a target price of Rs 230 and a stop-loss at Rs 197. 13 analysts are tracking the company, and they all maintain a 'buy' rating according to Bloomberg data. The average 12-month consensus price target implies an upside of 3.4%
Nilesh Jain from Centrum Broking Ltd has advised buying Macrotech Developers, commonly known as Lodha, with a target of Rs 1475 and a stop-loss at Rs 1385. Out of 18 analysts tracking the company, 13 maintain a 'buy' rating, four recommend a 'hold,' and one suggest 'sell,' according to Bloomberg data. The average 12-month consensus price target implies an upside of 1.7%
Lastly, Nilesh Jain recommends Biocon with a target price of Rs 400 and a stop-loss at Rs 369. Out of 19 analysts tracking the company, 11 maintain a 'buy' rating, three recommend a 'hold,' and five suggest 'sell,' according to Bloomberg data. The average 12-month consensus price target implies an upside of 3.4%
